Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 20:3:212.
doi: 10.3389/fimmu.2012.00212. eCollection 2012.

Immunomodulatory effect of mesenchymal stem cells on B cells

Marcella Franquesa  1 , M J Hoogduijn, O Bestard, J M Grinyó
Affiliations

Immunomodulatory effect of mesenchymal stem cells on B cells

Marcella Franquesa et al. Front Immunol. .

Abstract

The research on T cell immunosuppression therapies has attracted most of the attention in clinical transplantation. However, B cells and humoral immune responses are increasingly acknowledged as crucial mediators of chronic allograft rejection. Indeed, humoral immune responses can lead to renal allograft rejection even in patients whose cell-mediated immune responses are well controlled. On the other hand, newly studied B cell subsets with regulatory effects have been linked to tolerance achievement in transplantation. Better understanding of the regulatory and effector B cell responses may therefore lead to new therapeutic approaches. Mesenchymal stem cells (MSC) are arising as a potent therapeutic tool in transplantation due to their regenerative and immunomodulatory properties. The research on MSCs has mainly focused on their effects on T cells and although data regarding the modulatory effects of MSCs on alloantigen-specific humoral response in humans is scarce, it has been demonstrated that MSCs significantly affect B cell functioning. In the present review we will analyze and discuss the results in this field.

Keywords: B cells; MSC; chronic allograft rejection; humoral rejection; immunomodulation.

PubMed Disclaimer

References

    1. Asari S., Itakura S., Ferreri K., Liu C. P., Kuroda Y., Kandeel F., Mullen Y. (2009). Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37, 604.10.1016/j.exphem.2009.01.005 - DOI - PMC - PubMed
    1. Augello A., Tasso R., Negrini S. M., Amateis A., Indiveri F., Cancedda R., Pennesi G. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482.10.1002/eji.200425405 - DOI - PubMed
    1. Beggs K. J., Lyubimov A., Borneman J. N., Bartholomew A., Moseley A., Dodds R., Archambault M. P., Smith A. K., McIntosh K. R. (2006). Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons, Cell Transplant. 15, 711. - PubMed
    1. Chiesa S., Morbelli S., Morando S., Massollo M., Marini C., Bertoni A., Frassoni F., Bartolome S. T., Sambuceti G., Traggiai E., Uccelli A. (2011). Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 108, 17384.10.1073/pnas.1103650108 - DOI - PMC - PubMed
    1. Choi E. W., Shin I. S., Park S. Y., Park J. H., Kim J. S., Yoon E. J., Kang S. K., Ra J. C., Hong S. H. (2012). Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 64, 243.10.1002/art.33313 - DOI - PubMed